In collaboration with the Nephrology Department at the National Institute of Kidney Diseases & Urology (NIKDU), ZAS Corporation Ltd. hosted a Virtual CME on “Induction Therapy in Immunologically High-risk vs Low-risk Kidney Transplant Recipients.” Prof. Hüseyin Koçak from Akdeniz University Hospital, Antalya, Türkiye, joined virtually, providing valuable insights into personalized approaches in kidney transplant care. The event saw active participation from medical professionals, reflecting ZAS Corporation’s dedication to advancing healthcare education and expertise.
More Releases
ZAS Corporation Introduces Uro-Vaxom to Bangladesh: A Milestone in UTI Prevention
ZAS Corporation proudly launched Uro-Vaxom, an advanced immunotherapeutic solution by OM Pharma, Switzerland,...
ZAS Corporation Hosts Virtual CME on Kidney Transplant Induction Therapy
In collaboration with the Nephrology Department at the National Institute of Kidney Diseases & Urology...
ZAS Corporation Showcases Commitment to Oncology Care at MOSB Congress 2024
ZAS Corporation proudly participated in the prestigious MOSB Congress 2024, reaffirming its dedication...
ZAS Corporation Proudly Sponsors the 178th World Anesthesia Day Celebration with Bangladesh Society of Anaesthesiologists, Critical Care and Pain Physicians
ZAS Corporation was honored to serve as the core sponsor of the 178th World Anesthesia Day celebration,...
ZAS Corporation Celebrates 19th Anniversary with Team Participation
ZAS Corporation proudly marked its 19th anniversary, celebrating nearly two decades of excellence, innovation,...
Morinaga Research Centre Japan Visits Bangladesh to Strengthening Global Collaborations
We are thrilled to have welcomed our partners from the Morinaga Research Centre, Japan, to Bangladesh....
ZAS Corporation Secures Trademark for DECA Brand
We are proud to announce that ZAS Corporation Ltd. has officially secured the trademark for our brand...
ZAS Corporation Obtains Trademark for Protimeal Brand
We are delighted to announce that ZAS Corporation has successfully obtained the trademark for our brand...
ZAS Corporation Successfully Launches Celltrion Biosimilars in Bangladesh
We are proud to announce the successful launch of Celltrion’s biosimilar products in Bangladesh,...
ZAS Corporation Ltd. Unveils Vision for the Next Decade in Oncology at Sales Conference
Dhaka, Bangladesh – ZAS Corporation Ltd., a leading pharmaceutical company with a strong focus on oncology,...